IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

The Silent Battle: Antibiotic Resistance And Its Impact

Ms. Tanaya Jaipal Bhowate[1], Mr. Vikas Kunde[2]

1* Student, Pravara College of Pharmacy (For Women's), Chincholi, Nashik, Maharashtra.

2 Assistant Professor, Pravara College of Pharmacy (For Women's), Chincholi, Nashik, Maharashtra.

ABSTRACT

This study examines the pressing global health threat of antibiotic resistance (AMR), emphasizing its origins, mechanisms, and the multifaceted approaches needed to combat it. The emergence of AMR is largely driven by the inappropriate use of antibiotics, leading to resistance development in various bacterial populations. Horizontal gene transfer (HGT) plays a critical role in the dissemination of resistance genes among bacteria, exacerbating the challenge across healthcare settings, including community environments. The study highlights the impact of biofilms on infection persistence and resistance, as well as the complex evolutionary adaptations of bacteria to survive antibiotic pressure. Additionally, it reviews the mechanisms by which bacteria develop resistance, including enzymatic inactivation, alterations in drug targets, and efflux systems. The economic burden of AMR is substantial, affecting healthcare costs and patient outcomes, particularly in vulnerable populations. Factors contributing to resistance include over-prescription, self-medication, and environmental influences. Preventive strategies such as vaccination and the development of novel antibiotics, including nanoparticles, are discussed as potential solutions. The study calls for a collaborative One Health approach to monitor and address AMR in human health, agriculture, and the environment, underscoring the urgent need for innovative research and policy initiatives to mitigate this crisis.

KEYWORDS: Horizontal Gene Transfer (HGT), Biofilms, Genetic Determinants, Active Efflux, Nanoparticles.

INTRODUCTION

The significance of antibiotic resistance as a recurring threat to world health is discussed in this paper, along with initiatives to address this intricate issue. (1) The ability of a bacteria to withstand the antagonistic effects of an antibacterial agent, such as bactericidal or reproduction-prevention, is known as resistance. Overuse and improper administration of antibiotics can lead to the development of antibiotic resistance in microorganisms. Globally, antibiotic resistance is one of the biggest issues facing public health.(2,3,4) In recent decades, the emergence and spread of antibiotic resistance among pathogenic bacteria has become an increasingly pressing issue for public health.(5).In addition to having a significant positive influence on the treatment of infectious

diseases (such as community-acquired pneumonia caused by Streptococcus pneumoniae), antibiotics are now a necessary part of every facet of contemporary healthcare.(6) Genes encoding a resistance mechanism can be transferred directly or by mutation, leading to the development of resistance. Numerous mechanisms, such as conjugation (transfer of genes carried on Plasmids, also known as mobile genetic elements), transformation (direct transfer of naked DNA), and transduction (transfer of similar DNA by bacteriophage), can result in the transfer of resistance genes. (7) The development of antibiotic resistance does not occur solely in hospital settings. The lines separating traditional healthcare facilities from the community have blurred as healthcare systems have developed, making residential and nursing homes—as well as out-of-patient settings like dialysis and oncology day units—important reservoirs for resistant organisms (8). Research activity has increased in response to the recent World Health Day by The World Health Organisation, with the theme "Combat drug resistance: no action today means no cure tomorrow." Several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens. (9) Antibiotic resistance must be tracked and managed in human medicine as well as in animal husbandry, agriculture, and aquaculture. It is a true One Health concern. (6) Antibiotic resistance has a significant financial impact, but more concerningly, there is a serious lack of progress in the discovery of new antibiotics. (10) In order to slow the rise in antibiotic resistance, political goals, laws, therapeutic development, and educational programs are crucial(1). It is becoming more widely acknowledged that all pathogenic, commensal, and environmental bacteria, as well as mobile genetic elements and bacteriophages, form a reservoir of antibiotic resistance genes (ARGs) called the resistome, from which pathogenic bacteria can acquire resistance through horizontal gene transfer (HGT) (5). In recent decades, there has been an alarming rise in the number of multidrug-resistant bacteria, which can lead to major issues. There is an urgent need to identify methods to address bacterial resistance because the emergence of resistant illnesses caused by these bacteria has resulted in death and morbidity. (5)

Biofilms

When biofilms develop in medical equipment, they may become a source of infections. Researchers from all around the world have been inspired by the challenge posed by biofilms to suggest or create alternatives for controlling biofilms. (12) Because of the innate antibiotic resistance imposed by its lifestyle, pathogenic microbial biofilm is regarded as a global concern. (12) The difficulty presented by biofilms has inspired scientists worldwide to suggest or create substitutes for biofilm control. (12) Despite advancements in biofilm research, the use of antibiotics to treat biofilm infections is still a mystery. Previous studies on the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of antimicrobial agents offer valuable insights for devising an effective dosage schedule and mitigating the emergence of antibiotic resistance and tolerance in biofilm infections.(13) Antibiotic resistance mechanisms, including altering the absorption of the antibacterial agent and biofilm formation, as well as a variety of strategies, including the creation of novel antibiotic classes, combination therapy, the use of natural antibacterial compounds, and the use of nanoparticulate systems.(11)

HGT

Through horizontal gene transfer, pathogenic bacteria can develop resistance (HGT).(5) One of the main forces behind bacterial evolution is the acquisition of foreign DNA material through horizontal gene transfer (HGT), which frequently results in the emergence of antibiotic resistance. The majority of antimicrobial agents that are used in clinical settings are either naturally occurring or derived from environmental sources, primarily soil. Intrinsic genetic resistance determinants are present in bacteria that coexist with these molecules, and there is strong evidence that these "environmental resistomes" are a major source of antibiotic resistance genes that bacteria that are clinically relevant acquire.(14) Only a few clinically relevant bacterial species are able to naturally incorporate naked DNA to develop resistance, making transformation possibly the most straightforward type of HGT. Conjugation is a highly effective gene-transfer mechanism that occurs through cell-to-cell contact

and is frequently linked to the emergence of resistance in hospital settings. It is also likely to occur frequently in the gastrointestinal tract of patients receiving antibiotic therapy. Conjugation typically uses mobile genetic elements (MGEs) as a means of transmitting important genetic information, though direct chromosomal-to-chromosome transfer has also been thoroughly studied.(15) Through the acquisition of pre-existing AMR genes from commensal bacteria, HGT enables pathogenic bacteria to evolve resistance. The field is currently faced with challenges in better understanding the rate at which pathogens acquire AMR genes through horizontal gene transfer (HGT) and identifying the critical conduits that transfer AMR genes from commensal bacteria to pathogens. The fundamental mechanisms of HGT were discovered more than 50 years ago (16). Using innate barriers to AMR gene transfer as a weapon against HGT acquired AR is an alternate strategy. A variety of innate (restriction-modification) and adaptive (CRISPR-Cas) immune systems that recognise and eliminate incoming "non-self" DNA are among the xenogenic defence mechanisms that bacteria possess. (17)

Evolution of Antibiotic Resistance

Bacterial pathogens have been a major cause of disease and mortality for the majority of human history. Since their discovery, antibiotics have had a significant impact on human health and longevity by offering a quick and efficient therapy for bacterial illnesses. The emergence of antimicrobial resistance (AMR) poses a threat to this: Numerous harmful bacteria have developed resistance to the major antibiotic classes, and diseases that are incurable have been caused by pan-resistant bacteria. (18) There are two primary methods that have been applied to comprehend the mechanisms behind AMR's spread. Clinical research has concentrated on the epidemiological dynamics of resistance and DNA sequencing to find the genes underlying AMR. Experimental research, frequently aided by mathematical models, has concentrated on examining how AMR varies in response to specified and regulated selective pressures using basic in vitro model systems (19).

Resistance Due to Global Cell Adaptations

After millions of years of evolution, bacteria have created complex defence systems against pressures and stresses in their surroundings to enable them to live in the harshest settings—including the human body. To obtain the "upper hand," bacteria must fight for nutrients and fend off attacks from molecules made by competing organisms. The immune system of a given host continuously attacks bacterial organisms, and in order for them to establish themselves in specific biological niches, they must be able to adapt to and tolerate these stressful conditions. Bacterial pathogens have therefore evolved extremely intricate defence mechanisms to prevent the interference with essential cellular functions like membrane homeostasis and cell wall synthesis. Global cell-adaptive response to the antibacterial attack results in the development of resistance phenotypes, the most clinically relevant examples of which are vancomycin (low-level in S. Aureus) and daptomycin (DAP) resistance. The innate immune system produces cationic antimicrobial peptides, which are related to lipopeptide antibiotics like DAP. DAP works as a bactericidal agent by disrupting the homeostasis of the cell envelope (20).

MECHANISMS OF RESISTANCE TO ANTIBIOTICS:

a) Antibiotic inactivation through enzymatic means:

The majority of bacteria, both Gram-positive and Gram-negative, produce enzymes that break down antibiotics. One of the most significant resistance mechanisms is this enzymatic inactivation mechanism. The beta-lactamases, aminoglycosides, modifying enzymes (acetylase, fosforiaz, adenilaz, and enzymes) in this group break down beta-lactam antibiotics and keep producing more of them, which inactivates enzymes like erythromycin and chlo The changes that occur in the receptor that connected to the drug and the region of the connection 'Connection of the antibiotics' target areas are different. They can be various enzymes and ribosomes.

Among macrolide antibiotics, resistance linked to changes in the ribosomal target is most commonly observed. Penicillin resistance can arise from mutations in penicillin-binding proteins (beta-lactamase enzymes) as well as strains of Staphylococcus aureus, Streptococcus pneumoniae, Neisseria meningitidis, and Enterococcus faecium.Modifications to the target's beta-lactam structure, Quinolones, glycopeptides, macrolides, tetracycline and Rifampicin resistance is an important mechanism in the development (24,25,26,27).ramphenicol (21, 22, 23).

b) Target areas of the antibiotics:

The drug-binding receptor and the area of the connection known as the "target areas of the antibiotics" undergo distinct alterations. They could be ribosomes or different enzymes. Among macrolide antibiotics, resistance linked to changes in the ribosomal target is most commonly observed. Penicillin resistance can arise from mutations in penicillin-binding proteins (beta-lactamase enzymes) as well as strains of Staphylococcus aureus, Streptococcus pneumoniae, Neisseria meningitidis, and Enterococcus faecium.One significant mechanism in the development is changes in the structure of the target, beta-lactam, quinolones, glycopeptides, macrolides, tetracycline, and rifampicin resistance (24,25,26,27).

c) Drug flushing (Active Pump System):

Active pump systems are primarily responsible for the development of resistance in the tetracycline class of antibiotics. With an energy-dependent active pumping mechanism, tetracyclines are eliminated from cells and are unable to build up within them. The control over such resistance is chromosomal and plasmid-based. Quinolones, beta-lactam antibiotics, chloramphenicol, streptogramins, and 14-membered macrolides can all be successfully resisted by active pumping systems (25, 26, 28).

d) By employing a different metabolic route

In contrast to certain bacterial target modifications, a novel drug-susceptible pathway obviates the requirement for target development. Thus, resistance to trimethoprim and sulfonamide was observed. Instead of synthesising folate, bacteria can acquire the ability to prepare folate from their surroundings (22, 29).



Figure 2. Mechanism of Antibiotic resistance

IMPACT OF ANTIBIOTIC RESISTANCE:

There aren't many studies that address the impact of antibiotic resistance on mortality and public health costs, making estimations challenging. According to a conservative estimate from the US Centre for Disease Control and Prevention (CDC), at least 23,000 Americans lose their lives to antibiotic-resistant infections each year, impacting over two million people in the country (30).The most common multidrug-resistant bacteria in Europe, Streptococcus pneumoniae, Escherichia coli, Enterococcus faecium, Klebsiella pneumoniae, and Pseudomonas aeruginosa, are thought to cause *400 000 infections and 25 000 deaths annually, respectively (31).Effective antibiotics are essential to many areas of modern medicine; without them, many procedures like organ transplantation, hip replacement surgery, intensive care for preterm newborns, chemotherapy for cancer, and many more could not be carried out. Actually, one of the primary causes of morbidity and death in patients undergoing these procedures is infections brought on by bacterial strains that are resistant to drugs. Infections in cancer patients with chemotherapy-related neutropenia had high rates of antibiotic resistance, according to a 2014 University of Texas study (32–33).60%–70% of infections in neonatal intensive care units are caused by Staphylococcal species, most notably S. Epidermidis and S. Aureus. Several outbreaks of methicillin-resistant S. Aureus (MRSA) have been reported in these units. Common infections in these units are becoming more and more difficult, and occasionally impossible, to treat (33).Antibiotic resistance has a difficult economic impact as well because there are a number of factors that need to be considered. A higher need for more expensive antibiotics (treatment must switch to second or third-line drugs, which are nearly always more expensive) as well as specialised equipment, longer hospital stays, and patient isolation procedures are all consequences of increased resistance. Death and lost productivity are examples of societal costs.The estimated total unrefined economic cost of antibiotic resistance in Europe is at least 1.5 billion euros, of which hospital costs account for over 900 million euros. Forty percent of the total estimated cost was attributed to lost productivity as a result of illness or absence from work (31).

Factors Affecting Antibiotic Resistance:

The antimicrobial drug's sale is a significant industry. Every year, millions of pounds of antimicrobial agents worth billions of dollars are produced in the US. A growing number of diseases are becoming resistant to treatment due to the spread of drug resistance, which is a result of the massive amounts of antibiotics that are produced and used (35). Doctors frequently misuse antibiotics, particularly in hospital intensive care units (ICUs), which are quickly turning into havens for the emergence and spread of antibiotic resistance as a result of exposure to high levels of antibiotic use in a population with a high density. Antimicrobial agent resistance spreads to other humans in contact with them when patients are released from the hospital to continue taking their medications at home (36, 37). Numerous developing nations have also documented instances of antimicrobial agent prescriptions that are unnecessary and observed in industrialised nations, albeit for different reasons (38). This is a significant issue in developing nations where there is a dearth of highly qualified and trained medical professionals and where quacks with inadequate training or no education pose as medical professionals in remote areas. Self-medication is widespread in developing nations, and antibiotics are easily obtained from hawkers, market stalls, roadside stands, and pharmaceutical stores (39, 40). Antimicrobial resistance has been identified as a primary cause resulting from consumer self-medication. Patients follow the advice of friends, family, and erroneous media sources in an effort to control their own illness, which leads them to take antibiotics excessively or needlessly. Antibiotic underuse (suboptimal dosages) resulting from this practice typically increases selective pressure and antimicrobial resistance (41). Antibiotics weakened by hawkers' exposure to temperatures above 20 °C, harsh shipping conditions to the tropics or when placed out on hot payment, expired medications with new labels, occasionally disposed of without labels, or donated rather than destroyed—all of these situations, when used, contribute to the development and spread of antimicrobial resistance (42).Due to the massive rise in international travel over the past ten years, people may have come

into contact with resistant microbes in one nation and then transported them to another, where resistance may then spread. The resistant strains of Neisseria gonorrhoea, which have spread throughout the world from their origins in Asia and the Philippines, are a prime example (43).

Figure 3. Factors affecting Antibiotic Resistance

PREVENTION OF ANTIBIOTIC RESISTANCE:

Preventing the development of antibiotic resistance is a key objective when prescribing antibiotics for a medical condition. Three key processes lead to the eergence of antibiotic-resistant bacteria: the selection of naturally resistant strains, the acquisition of novel genes through horizontal or transposon gene transfer, and the selection of resistant variations (44). Therefore, avoiding the behaviours that lead to resistance would be the primary goal in its prevention; yet, this goal would be challenging to put into practice. Therefore, the two strategies used to prevent the establishment of resistance would be to stop the mechanisms that allow person-to-person dissemination and prevent the acquisition of resistance and selection of antibiotic-resistant varieties. In addition, health practitioners should inform patients, carers, and others about the proper use of antibiotics and the negative effects of overusing them in order to increase medication adherence and patient compliance (45).

Preventive Approaches:

1)Vaccines:

Because a vaccine strengthens the body's natural defences while an antibiotic functions independently of the body's defences, vaccines do not have the resistance issue that antibiotics do. However, novel strains might emerge that evade the immunity induced by vaccinations; for instance, yearly vaccination against influenza is required. Although theoretically promising, the efficacy of ant staphylococcal vaccines has been limited due to immunological variation amongst Staphylococcus species and the short half-life of produced antibodies. More potent vaccines are being developed and tested (46).

2)Others:

Acknowledging the need to decrease the use of antibiotics, the Australian Common Wealth Scientific and Industrial Research Organisation (CSIRO) has been developing two alternatives. Adding cytokines to animal feed in place of antibiotics is one way to prevent diseases (47).

FUTURE PROSPECTS – WHAT SHOULD BE DONE?

Studies on the creation of novel antibiotics and other strategies to reduce the resistance crisis should be prioritised due to the sharp rise in the rate at which antibiotic-resistant pathogens are emerging. It is very challenging to treat infections brought on by MDR pathogens with the current generation of antibiotics. As a result, researchers are now concentrating on using antibiotics in combination with nanoparticles, or nano antibiotics. Nanoparticles can act like tiny molecules to interact with bacterial cells, regulate cell membrane penetration, and/or block molecular pathways. These nano-antibiotics are a blessing to medicine and health because the nanoparticles either have an antibacterial effect or can enhance the action of antibiotics to treat various infections. They have relatively higher absorption, controlled release, and targeted administration. Since the current concentrations of nanoparticles that harm organisms' cells are too high for human use, appropriate research should be done to determine precise doses of nano-antibiotics in order to partially address the antibiotic resistance dilemma (48).

PRECAUTIONS TO BE TAKEN TO PREVENT ANTIBIOTIC RESISTANCE

Correct use of antibiotics is the best defence against antibiotic resistance. Use them only as necessary. Here are a few ways you can contribute:

•An antibiotic should not be taken for a virus.

•Never keep an antibiotic for use in the event of another illness.

•Acquire antibiotics precisely as directed. Never miss a dose. Continue with the treatment for the full duration, even if you begin to feel better.

• use an antibiotic that was prescribed for another person.

Healthcare professionals can also assist by: Only prescribing antibiotics when necessary, and only after the medication has been specifically targeted to the offending bacteria. Lowering resistance can also be achieved through other public health initiatives, such as prescribing medications only when necessary. Reducing the use of antibiotics in livestock is part of that. In order to stop the spread of these infections, healthcare providers must also take action. These germs are widespread in medical environments. They ought to always practise proper hygiene. Additionally, they must always employ infection control techniques. (49)

Figure 4. Precautions for preventing Antibiotic Resistance

CONCLUSION

This study underscores the urgent and multifaceted challenge of antibiotic resistance, a significant global health threat exacerbated by the overuse and misuse of antibiotics in both clinical and agricultural settings. The mechanisms underlying resistance, such as horizontal gene transfer, enzymatic inactivation, and biofilm formation, illustrate the complexity of this issue and highlight the need for innovative treatment strategies. The alarming rise of multidrug-resistant bacteria not only poses serious health risks, leading to increased morbidity and mortality, but also imposes a substantial economic burden on healthcare systems worldwide.

Efforts to combat antibiotic resistance must be comprehensive, integrating surveillance, education, and stewardship programs across human and veterinary medicine. The exploration of alternative therapies, including vaccines and nanoparticle-based antibiotics, presents promising avenues for future research. However, sustained global collaboration and commitment from policymakers, healthcare professionals, and the public are essential to mitigate the rise of antibiotic resistance and preserve the efficacy of existing antibiotics for future generations. Without immediate and coordinated action, the prospect of returning to a pre-antibiotic era looms ever closer, threatening the advancements made in modern medicine.

REFERENCE

1. Velez R, Sloand E. Combating antibiotic resistance, mitigating future threats and ongoing initiatives. J Clin Nurs 2016;(March).

2. Yüce A. Antimikrobiyal ilaçlara direnç kazanma mekaniz-maları. Klimik Dergisi 2001; 14:41-46.

3. Tenover FC, Hugles JM. The challenges of emerging infectious diseases development and spread of multiply resistant bacterial pathogens. JAMA 1996; 275:300-304.

4. Gold HS, Moellering RC Jr. Antimicrobial drug resistance. N Engl J Med 1996; 335:14451453.

5. von Wintersdorff CJ, Penders J, van Niekerk JM, Mills ND, Majumder S, van Alphen LB, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front Microbiol 2016;7(February):173.

6. Department of Health. Annual Report of the Chief Medical Officer. Volume 2. Infections and the Rise of Antimicrobial Resistance. Department of Health, 2011. http://media.dh.gov.uk/network/357/files/2013/03/CMO- Annual-Report-Volume-220111.pdf (6 September 2015,Date last accessed).

7. Livermore D. Can better prescribing turn the tide of resistance? Nat Rev Microbial 2004;2:73–8.

8. Rooney PJ, O'Leary MC, Loughrey AC, et al. Nursing Homes as a reservoir of extended spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009;64:635–41.

9. Chellat MF, Raguˇz L, Riedl R. Targeting antibiotic resistance. Angew Chem Int Ed Engl 2016;(March). Frontiers

10. Wise R, Piddock LJV. British Society of Antimicrobial Chemotherapy (BSAC). The BSAC Working Party on the Urgent Need Regenerating Antibacterial Drug Discovery Development. http://antibiotic-action.com/wp-content/Uploads/2011/07/TUN-Report.pdf (6 September 2015, date Last accessed).

11. Khameneh B, Diab R, Ghazvini K, Bazzaz BSF. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog 2016;95(February):32-42.

12. Ribeiro SM, Felicio MR, Boas EV , Goncalves S, Costa FF, Samy RP, et al. New frontiers for anti-biofilm drug development. Pharmacol Ther 2016;160 (April):133-44.

13. Hengzhuang W, Hoiby N, Ciof O. Pharmacokinetics and pharmacodynamics of antibiotics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo. Methods Mol Biol 2014;1147:239-54.

14. Manson JM, Hancock LE, Gilmore MS. 2010. Mechanism of chromosomal transfer of Enterococcus faecalis pathogenicity island, capsule, antimicrobial resistance, and other traits. Proc Natl Acad Sci USA 107: 12269–12274.

15. Manson JM, Hancock LE, Gilmore MS. 2010. Mechanism of chromosomal transfer of Enterococcus faecalis pathogenicity island, capsule, antimicrobial resistance, and other traits. Proc Natl Acad Sci USA 107:12269–12274.

16. J. Chen et al., Science 362, 207 (2018).

17. S. Doron et al., Science 359, eaar4120 (2018).

18. J. O´Neill, TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS. Review on Antimicrobial Resistance, (2016).

19. M. Baym et al., Science 353, 1147 (2016).

20. Pogliano J, Pogliano N, Silverman JA. 2012. Daptomycin-mediated reorganization of membrane architecture causes mis localization of essential cell division proteins. J Bacteriol 194:4494–4504.

21. Yüce A. Antimikrobiyal ilaçlara direnç kazanma mekaniz maları. Klimik Dergisi 2001; 14:41-46.

22. Mayer KH, Opal SM, Medeiros AA. Mechanisms of antibiotic resistance. In Principles and Practice of Infectious Diseases. Ed By GL Mandell, JE Bennett, R Dolin. Mandell, Douglas, and Bennett Õs Fourth ed. New York: Churchill Livingstone, pp 212-225, 1995.

23. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 2013; 12:22

24. Ayliffe GA. The progressive intercontinental spread of Methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997;24:S74-79.

25. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae Clin Infect Dis 1997; 24:S85-88.

26. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 2013; 12:22.

27. Oppenheim BA. Antibiotic resistance in Neisseria meningitidis. Clin Infect Dis 1997; 24:S98-101.

28. Nikaido H. Prevention of drug access to bacterial targets:Permeability barriers and active efflux. Science 1994; 264:382-388.

29. Jawetz E, Melnick JL, Adelberg EA. Medical Microbiology.East Norwalk, CT: Appleton & Lange, pp 137-167, 1995.

30. Centres for Disease Control and Prevention, US Department of Health and Human Services. Antibiotic resistance threats in the United States. Atlanta: CDC; 2013. Available from: http://www.cdc.gov/Drugresistance/pdf ar-threats-2013-508.pdf.

31. ECDC/EMEA. The bacterial challenge: time to react. Stockholm:European Center for Disease Prevention and Control; 2009.

32. Nesher L, Rolston KV. The current spectrum of infection in Cancer patients with chemotherapy related neutropenia.Infection. 2014;42(1):5–13.

33. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR,Walsh MC, et al. Neonatal outcomes of extremely preterm Infants from the NICHD Neonatal Research Network.Pediatrics. 2010;126(3):443–56.

34. Patel SJ, Saiman L. Antibiotic resistance in neonatal intensive Care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship. Clin Perinatol.2010;37(3):547–63.

35. CDC. Antibiotic resistance threats in the United States. Atlanta: United States Department of Health and Human Services, centers for disease control and prevention (US); 2019. International Journal of Current Pharmaceutical ResearchISSN-0975-7066 ,Vol 13, Issue 5, 2021

36. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134(4):298-314. Doi: 10.7326/0003-4819-134-4-200102200-00014, PMID 11182841.

37. Golkar Z, Bagasra O,Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. J Infect Dev Ctries. 2014;8(2):129-36. Doi: 10.3855/jidc.3573, PMID 24518621.

38. Michael CA, Dominey-howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health.2014;2:145. Doi: 10.3389/fpubh.2014.00145, PMID 25279369.

39. Bennadi D. Self-medication: a current challenge. J Basic Clin Pharm. 2013;5(1):19-23. Doi: 10.4103/0976-0105.128253, PMID 24808684.

40. Joshi MC, Shalini AS. A questionnaire based study of self-medication practices among young population. Res J Pharm Biol Chem Sci. 2011;2:761-6.

41. Ocan M, Obuku EA, Bwanga F, Akena D, Richard S, Ogwal-Okeng J, Obua C. Household antimicrobial self medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. BMC Public Health. 2015;15:742. Doi:10.1186/s12889-015-2109-3, PMID 26231758.

42. Kraemer SA, Ramachandran A, Perron GG. Antibiotic pollution in the environment: from microbial ecology to public policy. Microorganisms. 2019;7(6):180.doi: 10.3390/microorganisms7060180, PMID 31234491.

43. Michele C, Julia L, Luke S. Antimicrobial resistance in G7 countries and beyond: economic issues, policies and options for action. OECD; 2015. P. 1-75

44. Alam MM, Wahab A, Billah M, Muzahidul Islam. Antimicrobial Resistance Crisis and Combating Approaches. Journal of
Medicine.

45. Michael, Carolyn Anne D-H, Dale, Maurizio. The Antimicrobial Resistance
Crisis: Causes, Consequences, and Management. Frontiers. Frontiers; 2014

46. "Immunity, Infectious Diseases, and Pandemics—What You Can Do".
Homestead Schools. Com. Retrieved 2013-06-12.

47. "Science, Technology, genetics, research on biotechnology: December 2009". Biotechnolo.blogspot. com. Retrieved 2013-06-12.

48. Cars, Otto, Liselotte Diaz Högberg, Mary Murray, Olle Nordberg, Satya Sivaraman, Cecilia Stålsby Lundborg, Anthony, and Göran Tomson. "Meeting the Challenge of Antibiotic Resistance." The BMJ. British Medical Journal Publishing Group, September 18, 2008.

49. https://www.cedars-sinai.org/health-library/diseases-and-conditions/a/antibiotic-resistance.html